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     INTRODUCTION 
  Onchocerciasis (river blindness) is a debilitating infection 
that is caused by the filarial nematode   Onchocerca volvulus . 
Thirty-seven million individuals are thought to be infected 
with  O. volvulus ; more than 99% of whom reside in 30 endemic 
countries in West and Central Africa, with the remainder 
found in Latin America and the Arabian Peninsula.  1–  3   The 
parasite is transmitted to humans by vector blackflies of the 
genus   Simulium   whose larvae develop in fast-flowing, well-
oxygenated rivers and streams. Infective larvae are transmitted 
to the human host during a blood meal and typically mature 
after 1 year into macrofilariae, which can live inside the host 
for up to 14 years and release millions of microfilariae.  2,  4   The 
pathology that is associated with onchocerciasis is primarily 
caused by the accumulation of dead microfilariae in the skin 
and eyes; clinical manifestations include visual impairment, 
in some cases permanent blindness, and onchocercal skin dis-
ease, which is associated with severe itching, dermatitis, and 
depigmentation. 
  Moxidectin is a macrocyclic lactone drug derived from the 
actinomycete   Streptomyces cyanogriseus   spp.   noncyanogenus  
that is currently being developed in collaboration with the 
World Health Organization for the treatment of onchocer-
ciasis in humans. The drug was initially developed as a vet-
erinary product for the treatment of canine heartworm and 
for the treatment of internal and external parasites in cat-
tle, sheep, deer, and horses.  5   Studies have indicated that 
moxidectin may exert its antiparasitic action by binding to 
glutamate-gated chloride channels, leading to hyperpolariza-
tion of muscle and nerves, and ultimately to paralysis and 
parasite death.  6,  7   Moxidectin also shows activity at the gamma-
aminobutyric acid (GABA) receptor complex, where it acts as 
an agonist and may stimulate the binding of the neurotrans-
mitter GABA that leads to parasite death.  8  
  It is important that human safety and pharmacokinetic (PK) 
parameters are fully examined for moxidectin. The first-in-
man (FIM) study in which single moxidectin doses of 3, 9, 18, 
or 36 mg were administered to healthy volunteers, assessed the 
safety, tolerability, and initial PK of an orally administered liq-
uid formulation in both the fed and fasting state.  5   Moxidectin 
was generally well tolerated, the peak plasma concentration 
(C  max  ) and the total area under the concentration-time curve 
(AUC) were linear and dose-proportional, the apparent vol-
ume of distribution (Vλ  z  /F) was large (2,080–3,549 L), and 
the t  ½   was long (485–842 h). The PK parameters and safety of 
moxidectin was confirmed in a further study in which healthy 
subjects received moxidectin in either a liquid or tablet formu-
lation.  9   Administration of moxidectin as a tablet reduced C  max  
and AUC by 22% compared with administration of the liquid 
formulation, with a delay in time to maximal plasma concen-
tration (t  max  ) of ~1 hour, as would be anticipated for a drug 
with low solubility, such as moxidectin. 
  The FIM study indicated that consumption of food might 
delay and increase the absorption of moxidectin as the t  max  
and AUC were significantly higher in the fed cohort com-
pared with the fasting cohort in a small number of subjects.  5  
Moxidectin has low solubility in water. Administration with 
high-fat meals can potentially increase bioavailability caused 
by increased solubilization of the drug in the intestinal lumen.  10  
Studies in a rat model have shown increased absorption of 
DDT after a high-fat meal, presumably caused by binding of 
the DDT molecule to triglyceride-rich lipoproteins, which 
assemble in the gut after a high-fat meal and are subsequently 
absorbed by the lymph.  11   The currently intended field of use 
of moxidectin is community-directed treatment of the eligible 
population in areas of   O. volvulus   transmission. Adherence to 
instructions regarding consumption in the fasted or fed state 
cannot be expected and consequently it is important that the 
effects of food on the bioavailability of moxidectin are thor-
oughly evaluated to assess potential implications for efficacy 
and safety. 
   MATERIALS AND  METHODS 
  Ethics  and  consent.     The study protocol was reviewed and 
approved by CPP Ouest VI, CHU Cavale Blanche (Brest, 
France) and was carried out in accordance with the ethical 
principles set out in the Declaration of Helsinki, and the good 
clinical practice guidelines established by the International 
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Conference on Harmonisation. All subjects provided informed 
written consent for participation in the study. 
   Subjects.     Inclusion criteria required subjects to be healthy 
(determined by the investigator on the basis of medical history, 
physical examination, clinical laboratory test results, vital 
signs measurements, and 12-lead electrocardiogram [ECG] 
findings); to be men or women of non-childbearing potential; 
to be 18–50 years of age at the time of screening; to have a body 
mass index of 18–30 kg/m  2   and a body weight of at least 50 kg; 
to be non-smokers or smokers of < 10 cigarettes per day; and 
to have alanine aminotransferase, aspartate aminotransferase, 
and creatinine levels below the upper limit of normal at the 
time of screening. Exclusion criteria included presentation of 
any of the following: significant cardiovascular, hepatic, renal, 
respiratory, gastrointestinal, endocrinological, immunologi-
cal, dermatological, hematological, neurological, or psychiatric 
disease; acute disease, including nausea and vomiting, within 
7 days of study Day 1; any surgical or medical condition that 
could interfere with the absorption, distribution, metabolism, 
or excretion of moxidectin; a positive urine drug screen or 
positive test results for human immunodeficiency virus (HIV), 
hepatitis B, or hepatitis C. 
   Study  design.     This study was a single-dose, randomized, 
open-label, parallel-group, inpatient/outpatient study con-
ducted in healthy subjects enrolled at one investigational 
center in France. All subjects were included in a pre-dose 
screening evaluation (carried out up to 3 weeks before the 
administration of moxidectin), a 48-h inpatient period, and 
an outpatient follow-up period for safety and PK for up to 
90 days after dosing. Subjects were randomized to receive 
a single oral dose of moxidectin in tablet form (8 mg) 
administered on Day 1 with 240 mL of room temperature 
water under fasting conditions (defined as an overnight fast 
of at least 10 h) or fed conditions (defined as an overnight 
fast of at least 10 h followed by a U.S. Food and Drug 
Administration-recommended high-fat breakfast; moxidectin 
was administered to subjects in the fed state within 5 minutes 
of consumption of the breakfast). 
   Analysis  of  PK  parameters.     Serial blood samples were 
collected for ~90 days after dosing. The concentrations of 
moxidectin present in the plasma were determined using a 
validated high-performance liquid chromatography with a 
fluorescence detection method as previously described.  12   The 
range of quantification was 0.08–120 ng/mL and abamectin 
was used as an internal standard. The inter-day accuracy 
(mean bias) and precision (coefficient of variation [%]) for 
moxidectin concentrations in plasma were < 6.4% and 13.1%, 
respectively. The mean recovery of moxidectin from plasma 
samples measured at the four quality control levels was 84.6%. 
No potential interference was detected from six different lots 
of plasma. 
  The plasma concentration-versus-time data following oral 
administration of moxidectin were determined using non-
compartmental methods (WinNonlin, version 5.1.1, Pharsight, 
Sunnyvale,  CA   ).  The  C max   and t  max   of moxidectin were deter-
mined directly from the observed plasma concentration data. 
The terminal-phase disposition rate constant (λ  z  ) was esti-
mated by a log linear regression of the terminal monoexponen-
tial portion of the observed plasma concentrations. The t  ½   was 
calculated as 0.693/λ  z  . The AUC at time T (AUC  T ),  truncated 
at the last measurable concentration at time T (C  T  ) was calcu-
lated using the trapezoidal rule during the ascending portion 
of the curve and the log trapezoidal rule during the descending 
portion of the curve. The AUC was then estimated from zero to 
infinity as AUC = AUC  T   +  λ  z  . The apparent oral dose clearance 
(CL) adjusted for bioavailability (F) (CL/F) was calculated as a 
ratio of moxidectin dose to AUC. The apparent volume of dis-
tribution based on the terminal phase (Vl  z  ) adjusted for bio-
availability (Vl  z  /F) was estimated as the ratio of CL/F to λ  z . 
   Analysis  of  pharmacodynamic  parameters.    The  pharma-
codynamic relationship between treatment with moxidectin 
and the Q wave-T wave (QT) interval in an ECG was 
investigated graphically using plots that showed the time-
course of moxidectin and QT correction (QTc), based on 
Fridericia’s formula (QTcF) and a population-specific QT 
correction (QTcN) formula. Parallel groups were pooled for 
the QT evaluation. 
   Safety.     The investigator recorded the frequency and severity 
of all adverse events (AEs), and provided opinion on the 
relationship of the AEs to the study drug. 
   Statistical  analyses.     Summary statistics were calculated for 
the PK parameters. To test for differences between the fed 
and fasting results, an analysis of variance on log-transformed 
parameters with fasting/fed treatment as a fixed effect was 
performed. If no difference in C  max   and AUC was found then 
two one-sided   t   test procedures were carried out for C  max   and 
AUC using 90% confidence intervals about the geometric 
mean ratio of the recorded PK measure of moxidectin in the 
fed group and the recorded PK measure of moxidectin in the 
fasting group to assess adherence to bioequivalence. 
    RESULTS 
    Subject disposition and demographics.    The  demographic 
and baseline characteristics of subjects are shown in   Table 1  . 
Fifty-four eligible male subjects were enrolled in the study and 
were randomized to receive moxidectin (8 mg) in the fasted 
state (  N   = 27) or in the fed state (  N   = 27). Fifty-three subjects 
completed the study and were included in the PK analyses. 
One subject withdrew from the fed cohort on study Day 4. 
 Table 1 
  Demographic  and  baseline  characteristics *   
Characteristic
Moxidectin 8 mg
Fasted (  N   = 27) Fed (  N   = 27) Total (  N   = 54)
Age (years)
  Mean (SD) 30.4 (9.5) 30.9 (10.7) 30.7 (10.0)
 Range 19.0–50.0 19.0–50.0 19.0–50.0
Sex, n (%)
  Male 27 (100) 27 (100) 54 (100)
Race, n (%)
  White 26 (96.3) 26 (96.3) 52 (96.3)
 Black  or  African 
American
0 1 (3.7) 1 (1.9)
  Mixed race 1 (3.7) 0 1 (1.9)
Baseline height (cm)
  Mean (SD) 179.9 (7.6) 174.9 (6.5) 177.4 (7.4)
 Range 163.0–194.0 160.0–189.0 160.0–194.0
Baseline weight (kg)
  Mean (SD) 75.7 (12.0) 70.7 (9.5) 73.2 (11.0)
 Range 58.0–106.6 56.5–89.2 56.5–106.0
BMI (kg/m  2 )
  Mean (SD) 23.3 (2.6) 23.1 (2.4) 23.2 (2.5)
 Range 19.9–29.9 18.0–28.4 18.0–29.9
    *      BMI = body mass index, calculated as weight (kg)/(height [m]  2  ); SD = standard 
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Concentration measurements for this subject have been 
included in the summary of concentrations, but corresponding 
PK parameters could not be calculated and have not been 
included in the summary of PK parameters. All subjects were 
included in the safety analyses. 
        P K .      The mean concentration-time profiles after admin-
istration of single oral doses of moxidectin in the fasting 
and fed states are shown in   Figure 1  . After administration 
of moxidectin to subjects in the fed cohort, the mean C  max  
increased by 34% (  P   = 0.001), t  max   was delayed by 43% (1.6 h; 
  P   < 0.05), AUC was increased by 44% (  P   < 0.05), CL/F 
decreased by 35% (  P   = 0.0009), and Vl  z  /F decreased by 40% 
(  P   = 0.0003) when compared with fasting subjects (  Table 2  ). 
         Safety.     Thirty-three subjects (61.1%) experienced at least 
one AE during the study and of these, 29 (53.7%) experienced 
treatment-emergent AEs (TEAEs): 15 (55.6%) in the fasted 
cohort and 14 (51.9%) in the fed cohort. Eleven of these 29 
subjects experienced TEAEs that were considered by the 
investigator to be drug related, all of which were mild in 
intensity. The most commonly reported drug-related TEAEs 
(defined as ≥ 5% of subjects in either the fed or fasted cohorts) 
were headache (three [11.1%] subjects in the fasted cohort), 
flatulence (two [7.4%] subjects in each of the fasted and fed 
cohorts), and asthenia (two [7.4%] subjects in the fed cohort). 
One subject withdrew from the study for personal reasons; no 
subject was withdrawn because of safety-related AEs and no 
serious AEs (SAEs) were reported during the study. There 
were no clinically important changes in laboratory evaluations, 
vital signs, or ECGs. 
   Pharmacodynamics.     No statistically significant increases in 
QTc or an upper bound greater than 10 ms were reported for 
either QTcN or QTcF at any time point (  Table 3  ). At 1-hour 
and 2-hour time points, both QTcN and QTcF showed a 
statistically significant decrease in QTc. 
         DISCUSSION 
  This open-label, randomized, single-dose, parallel-group, 
inpatient/outpatient study in 54 healthy male subjects was 
performed to assess the relative bioavailability of moxidectin 
administered during the fasting state or after consumption of 
a high-fat meal, and to determine the safety and tolerability 
of the drug. 
  The PK parameters reported here are generally consistent 
with those observed in the FIM study of the liquid formula-
tion of moxidectin that was conducted in 37 healthy subjects 
in the fasted state or after consumption of a high-fat meal,  5  
which showed that in the fed state, administration of 9 and 
36 mg of liquid moxidectin exhibited a mean AUC that was 
33% and 64% higher, respectively, compared with adminis-
tration of moxidectin during the fasting state, with no corre-
sponding increase in C  max  . Consistent with these observations, 
mean AUC was 44% higher in this study of moxidectin at 
a dose of 8 mg in individuals who were fed a high-fat meal 
compared with those in the fasting state. However, in con-
trast to the previous study, the mean C  max   was 34% higher in 
the subjects who received moxidectin with food, compared 
with those subjects who received moxidectin while fasting. 
This higher C  max   is probably a result of the slower absorp-
tion of moxidectin in tablet form compared with the liquid 
formulation (t  max   of 3.2 h versus 2.3 h, respectively), allowing 
improved bioavailability as a result of food administration to 
become more evident. 
  The simultaneous lower values in mean observed CL/F and 
Vl  z  /F (35% and 40%, respectively) in fed subjects suggest that 
consumption of food results in a change in drug bioavailabil-
ity rather than a change in intrinsic clearance. The reported 
increase in bioavailability could be a result of inhibition of 
efflux transporters in the intestine or because of increased sol-
ubilization of the drug in the intestinal lumen.  10  
 Figure 1.        Mean ± SD moxidectin concentration in healthy volun-
teers after an oral 8 mg dose while fasting or with food.       
 Table 2 
    Moxidectin pharmacokinetics in healthy subjects after single 8-mg doses (mean [SD])   
C  max   (ng/mL) t max   (h) λ  z   (h) t ½   (h) AUC (ng.h/mL) CL/F (L/h) Vl  z /F  (L)
Fasted (  N   = 27) 58.9 (12.5) 3.7 (1.5) 0.00107 (0.00061) 784 (347) 3387 (1328) 2.76 (1.28) 2829 (1267)
Fed (  N   = 26) 79.1 (26.3)  *  5.3 (2.1)  *  0.00117 (0.00046) 700 (307) 4885 (1483)  *  1.78 (0.54)  *  1708 (724)  * 
    *     Significantly different to fasted value,   P   < 0.05.   
    SD = standard deviation; C  max   = peak plasma concentration; t  max   = time to C  max ;  λ  z   = terminal-phase disposition rate constant; t    ½     = terminal-phase elimination half-life; AUC = area under 
concentration-time curve; CL/F = apparent oral dose clearance; Vl  z  /F = apparent volume of distribution.   
 Table 3 
    Statistical summary of QTc differences from baseline by time point  *     
QTcN QTcF
Time point (h) Estimate (ms) 90% CI (ms) Estimate (ms) 90% CI (ms)
1 −5.6 −8.1 to −3.2 −5.5 −8.1 to −2.8
2 −4.1 −6.6 to −1.7 −4.1 −6.8 to −1.5
4 −1.0 −3.5 to 1.4 −1.2 −3.9 to 1.5
6 1.3 −1.2 to 3.7 1.2 −1.5 to 3.8
8 0.2 −2.3 to 2.7 0.2 −2.5 to 2.8
12 −1.2 −3.7 to 1.2 −1.1 −3.8 to 1.6
24 −2.3 −4.7 to 0.2 −2.5 −5.2 to 0.1
    *     QTc = Q wave-T wave interval correction; QTcN = population-specific Q wave-T wave 
correction; QTcF = Q wave-T wave correction using Fridericia’s formula; CI = confidence 
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  In this study, moxidectin was reported to be generally well 
tolerated in both the fasted and fed cohorts. Drug-related 
TEAEs were relatively infrequent, similarly distributed across 
the fasted and fed cohorts, and were similar to those reported 
in a previous phase I clinical study.  9  The TEAEs reported dur-
ing the inpatient and long outpatient phases were generally 
found to be mild seasonal infections that took place during 
the outpatient phase. No SAEs were reported during the study 
and no subject withdrew from the study as a result of AEs. 
There were no clinically relevant changes in vital signs, safety 
laboratory tests, and ECGs (no prolongation of the QTc inter-
val) during this study. 
 This study shows that consumption of food increases the bio-
availability of moxidectin compared with drug   administration 
in the fasting state. In addition, moxidectin was found to be 
generally well tolerated when taken in tablet form, with or 
without food. Furthermore, the known safety profile of moxi-
dectin in both healthy volunteers and patients suggests that 
the clinical impact of administration with food in subsequent 
clinical trials of moxidectin should be minimal. A phase III trial 
of moxidectin for the treatment of onchocerciasis in humans 
is ongoing. 
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